financetom
Business
financetom
/
Business
/
Dolby Laboratories marginally beats Q4 revenue expectations
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Dolby Laboratories marginally beats Q4 revenue expectations
Nov 18, 2025 5:51 PM

Overview

* Dolby Laboratories Q4 2025 revenue slightly beats analysts' expectations

* Adjusted EPS and adjusted net income beat analysts' estimates

* Dolby ( DLB ) repurchased 479,000 shares for $35 mln, $277 mln worth of repurchase authorization available

Outlook

* Dolby estimates Q1 2026 revenue between $315 mln and $345 mln

* Company expects full-year 2026 revenue between $1.39 bln and $1.44 bln

* Dolby anticipates Q1 2026 diluted GAAP EPS between $0.39 and $0.54

Result Drivers

* TECHNOLOGY ADOPTION - Growth driven by increased adoption of Dolby Atmos and Dolby Vision in TVs and streaming services

* NEW PATENT POOL - Introduction of new imaging patent pool for content streamers expanded addressable market

* PARTNERSHIPS - Agreements with automakers and streaming platforms enhanced market presence

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q4 Slight $307 mln $304.70

Revenue Beat* mln (4

Analysts

)

Q4 Beat $0.99 $0.70 (3

Adjusted Analysts

EPS )

Q4 Beat $96 mln $66.69

Adjusted mln (2

Net Analysts

Income )

Q4 Net $49 mln

Income

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the software peer group is "buy"

* Wall Street's median 12-month price target for Dolby Laboratories Inc ( DLB ) is $97.50, about 33.8% above its November 17 closing price of $64.55

* The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 18 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Column: The first video game addiction lawsuit got knocked out. Will others follow?
Column: The first video game addiction lawsuit got knocked out. Will others follow?
Jun 21, 2024
(The opinions expressed here are those of the author, a columnist for Reuters.) By Jenna Greene June 21 (Reuters) - When my twenty-something son was a teenager, there was a period when he played video games for hours on end, bristling when we told him to stop. Which is why I can relate to allegations in a series of personal...
GM's self-driving Cruise unit to pay $112,500 for delaying crash report
GM's self-driving Cruise unit to pay $112,500 for delaying crash report
Jun 21, 2024
(Reuters) -A California regulator said on Thursday it is imposing the maximum penalty of $112,500 on General Motors' self-driving Cruise unit for the company's failure to promptly provide complete information to the commission about a serious crash involving one of its robotaxis last year. WHY IT'S IMPORTANT Cruise along with other self-driving vehicle companies like Alphabet's Waymo and Amazon's Zoox...
Update: Capital One, Walmart Settle Suit Over Credit Card Partnership
Update: Capital One, Walmart Settle Suit Over Credit Card Partnership
Jun 21, 2024
02:02 PM EDT, 06/21/2024 (MT Newswires) -- (Updates with Walmart's ( WMT ) response in the fourth paragraph.) US District Court for the Southern District of New York Judge Katherine Polk Failla on Thursday dismissed all claims in a lawsuit between Capital One Financial ( COF ) and Walmart ( WMT ) over the companies' credit card partnership. In 2018,...
Weight-loss drug Zepbound resolves sleep apnea in up to 52% of patients, Lilly says
Weight-loss drug Zepbound resolves sleep apnea in up to 52% of patients, Lilly says
Jun 21, 2024
June 21 (Reuters) - Eli Lilly ( LLY ) on Friday said its popular weight-loss drug Zepbound helped resolve moderate to severe obstructive sleep apnea in up to 52% of patients in two late-stage trials. U.S.-based Lilly and Danish rival Novo Nordisk are in a race to get their obesity drugs approved to treat other ailments. Novo's Wegovy was approved...
Copyright 2023-2026 - www.financetom.com All Rights Reserved